Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Primex Media Services awarded as the Fastest Growing PR Agency Business
  • Former cricketer Munaf Patel joins KP Group as brand ambassador Business
  • VABB- A non-invasive advanced technique to remove benign breast lumps Business
  • Pro-partner, a revolution in retail property investment by Rashmi Group Business
  • Intex Launches Its flagship First WebOS TV in two sizes with Dolby Audio Business
  • Anglo French Drugs & Industries Limited Launches AFD: Pulmo Range in Respiratory Care Business
  • The Art Of Dumpling has won the Most Promising Pan Asian Cuisine Restaurant of the Year – 2022, New Delhi by Business mint Lifestyle
  • Sharan Hegde becomes the first-ever Finfluencer (Financial Influencer) to launch his own NFT Business

Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Posted on April 27, 2021 By dsprime 10 Comments on Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

English, Health Tags:DrDSrinivasReddy, OptimusPharmaSeeks, PNN

Post navigation

Previous Post: Indian Leadership Academy – A one-stop destination for all your training and coaching needs in Leadership and mindful learning
Next Post: XERTZ launches first-ever true wireless stereo technology-based Audio-frame glasses and sunglasses for the Indian market

Related Posts

  • Concept Investwell Private Limited – A company that helps Investors in Investing ‘WELL’. Business
  • Chef Taruna Birla launches her Cookery Book Education
  • Entrepreneur “Ansh Handa” achieves new heights of success in Digital Business A
  • XERTZ launches first-ever true wireless stereo technology-based Audio-frame glasses and sunglasses for the Indian market Business
  • SmartBike Launches Its Electric and NextGen Bikes in Chennai English
  • Ashish Mehta is helping big corporations to an ordinary man with his Vedic knowledge of Astro – Vastu English

Comments (10) on “Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India”

  1. marizon ilogert says:
    October 10, 2022 at 7:08 am

    Thank you for another fantastic article. Where else could anyone get that type of information in such a perfect way of writing? I have a presentation next week, and I am on the look for such info.

  2. How to Start a Brazing Machines (gas) Business (Beginners Guide) says:
    December 16, 2022 at 9:35 am

    I’ve been exploring for a bit for any high quality articles or blog posts in this sort of area . Exploring in Yahoo I eventually stumbled upon this site. Studying this info So i’m glad to express that I’ve a very just right uncanny feeling I came upon just what I needed. I so much for sure will make sure to don’t disregard this website and provides it a glance on a continuing basis.

  3. The Best Breakfast Places in Chisinau (Moldova) says:
    December 17, 2022 at 12:20 pm

    We are a bunch of volunteers and starting a new scheme in our community. Your web site provided us with helpful information to paintings on. You have done an impressive activity and our entire neighborhood might be grateful to you.

  4. Sellaite - Ultimate Knowledge Handbook (Mineral Guide) says:
    December 21, 2022 at 3:34 am

    I think you have mentioned some very interesting details, regards for the post.

  5. Learning and Understanding about Ocular albinism Disease (Volume 1) says:
    December 21, 2022 at 9:03 pm

    Thanks for sharing superb informations. Your site is so cool. I am impressed by the details that you’ve on this web site. It reveals how nicely you understand this subject. Bookmarked this web page, will come back for more articles. You, my pal, ROCK! I found just the information I already searched all over the place and just could not come across. What a perfect website.

  6. The Best Dessert Places in Yaounde (Cameroon) says:
    December 21, 2022 at 11:41 pm

    I was looking through some of your posts on this website and I think this internet site is really instructive! Keep on putting up.

  7. How to Write a Business Plan for a Copper Ore And Concentrate Extraction And Preparation Business says:
    December 24, 2022 at 11:27 pm

    As a Newbie, I am constantly searching online for articles that can be of assistance to me. Thank you

  8. How to Become a Plug Wirer says:
    December 26, 2022 at 7:49 pm

    I’d have to examine with you here. Which is not one thing I usually do! I take pleasure in reading a post that may make folks think. Additionally, thanks for permitting me to comment!

  9. The Best Places to Work in Qujing (China) says:
    December 31, 2022 at 11:23 am

    A large percentage of of whatever you state happens to be astonishingly legitimate and it makes me wonder why I had not looked at this in this light before. This piece truly did switch the light on for me as far as this specific subject goes. Nevertheless there is one issue I am not really too comfy with and whilst I try to reconcile that with the actual main theme of the position, permit me observe just what the rest of the readers have to point out.Well done.

  10. Beginners Guide to Growing Scrophularia (figwort) (Home & Garden Handbook) says:
    January 4, 2023 at 12:23 am

    I don’t even know the way I ended up here, but I believed this publish was great. I don’t realize who you’re however certainly you’re going to a famous blogger if you aren’t already 😉 Cheers!

Leave a Reply Cancel reply

Your email address will not be published.

Recent Posts

  • Yokogawa Enters Investment and Collaboration Agreement with Ideation3X, a Startup Taking a Circular Economy Approach to Waste Management in India
  • Shri Keshav Cement & Infra 9m FY23 net profit up 348%
  • India’s Youngest Entrepreneur Mohammad Afzan Hasan Purchased a New VIP Car
  • Sushim Gaikwad & Karan Rajora win Dada Saheb Phalke IT award 2023 for best production house
  • RupeeBoss Financial Services launches “MSME Bharat Manch” – A Nation-wide Initiative to Empower MSMEs

Recent Comments

  • форма Barcelona купить в Москве on Gururo.com collaborates with IU University, Germany to Offer World-Class Post Graduate Certificate in Program Management
  • Oyftjd on Azeez Abdulla’s biography on PM Narendra Modi to hit the shelves soon
  • Wnlkgj on Inrate Broadens Coverage and Is Poised for Growth With New Global Reach
  • medicijnen kopen on VGL Launches Search for Next Big Product Idea
  • link slot online hari ini on WardWizard Innovations Mobility Ltd Aims to benefit by EV regulations for Aggregators; Declares Excellent Results
  • Niket Patel, A Young Social Worker Conferred with Rajiv Gandhi Award In Delhi Press Release
  • Another edition of the luxurious calendar – ILF Calendar 2022 unveiled by India Luxury Foundation Lifestyle
  • BoM Organises Meeting on the Customer Rights and Grievance Redressal Mechanism Under the RBI Nationwide Intensive Awareness Campaign Business
  • Focally unveils the world’s first Full-colour Micro-led based true AR glasses with fully see-through display and USound MEMS speakers’ technology Business
  • Sun Interiors Pune Redefining Interior Designing Solutions for Residential Properties in Pune Business
  • Badthameez Store offers 10% discount on the first order Business
  • An oxygen park for Parkinson’s, MS patients at Sushrut hospital set up by Greenman Viral Desai Press Release
  • Athflex Rolls out Its Exclusive Range of Performance-cum-leisure Wear Lifestyle

Copyright © 2023 Daily News India.

Powered by PressBook News WordPress theme